ClinicalTrials.gg
RecruitingNCT07297290MOWRIUpdated Dec 22, 2025

Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)

A Phase 3 interventional study of Metformin and Placebo in Obesity and Cardiovascular Risk, Insulin Resistance and Obesity (Body Mass Index >30 kg/m2), sponsored by University Of Nigeria Teaching Hospital. Recruiting at 2 sites in Nigeria. Open to participants aged 20 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by University Of Nigeria Teaching Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
20 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies testing metformin in Obesity — 15 open to participants now, 17 under way, 3 of them phase 3. Metformin · Obesity.

Planned enrollment
8th of 81
220 · median 62
Started
2025
with 4 others
Phase 3
10 of 81
3 open now
Primary completion
2027-03
later than 10 of 16 live
Registered
73rd of 81
by date

Among the 81 studies testing metformin in Obesity, this one is the 8th largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 10 of the 16 other live ones, and was the 73rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

15 of the 81 studies testing metformin in Obesity are open now, in 9 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 20 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies testing metformin in Obesity, or all of them as a file.
02

Study summary

Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.

Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.

03

Conditions studied

  • Obesity and Cardiovascular Risk
  • Insulin Resistance
  • Obesity (Body Mass Index >30 kg/m2)

Keywords

  • Obesity
  • Metformin use
  • Weight loss
  • Non-diabetic
04

Who can participate

Ages eligible
20 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Obesity (defined as ≥ 30kg/m2),

      • Fasting plasma glucose (\<7.0mmol/L)
      • No medical treatment for weight control in the previous 12 months
      • No participation in a current clinical trial

Exclusion criteria

Exclusion Criteria:

    • Obesity (defined as ≥ 30kg/m2),

      • Fasting plasma glucose (\<7.0mmol/L)
      • No medical treatment for weight control in the previous 12 months
      • No participation in a current clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Treatment arm

    Metformin 500mg extended release tablets taken once daily to a maximum dose of 1500mg daily

    Drug: Metformin

  • Placebo comparator
    Control arm

    Identical-looking placebo

    Drug: Placebo

Interventions

  • Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily

  • DrugPlacebo

    Starch-based, identical looking placebo

06

What researchers measure

Primary outcomes

  1. Effect of Metformin on body weight change

    Determine percent change in body weight in kilograms and height in meters which will be combined to report BMI in kg/m2 among the treatment arm and compared to the control arm.

    Time frame: 24 months

  2. Effect of Metformin on Cardiovascular risk

    Determine percent change in the 10 year Framingham risk score for cardiovascular disease among the treatment arm and compare with the control arm.

    Time frame: 24 months

  3. Effect of Metformin on insulin resistance in non-diabetics

    Determine percent change in the insulin resistance indices using Homeostatic model assessment (HOMA) among the treatment arm and compare to the control arm.

    Time frame: 24 months

  4. Effect of metformin on waist circumference change

    Determine the percent change in waist circumference measured in cm at baseline and final readings among the treatment arm and compared to the control arm.

    Time frame: 24 months

  5. Effect of metformin on waist-to-hip circumference change

    Determine the percent change in waist circumference measured in cm, and hip circumference measured in cm, which will be combined to report waist-to-hip circumference ratio change among the treatment arm and compared to the control arm.

    Time frame: 24 months

Secondary outcomes

  1. Safety of Metformin extended release tablet taken daily

    Determine the incidence of adverse effects at grade 3 or higher level using the Adverse Effect questionnaire when dosage of less than or equal to 1500mg of Metformin X extended release tablet is taken daily.

    Time frame: 24 months

  2. Percent drug compliance to Metformin extended release taken once daily.

    Determine the percent drug compliance to administered Metformin extended release tablets, determined by count of actual number of drug tablets administered over count of what was expected to have been administered, expressed as a percentage.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol, statistical analysis plan, informed consent form, Non-identifiable patient measurements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available after publishing of the research work likely from 1 Jan 2029 for 5 years (31 Dec 2033)

Access criteria: The research institution, the research funders, potential collaborators and funders.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 20 months after the start.

Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 20 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Dec 22, 2025
StartActual
Jul 23, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297290
Lead sponsor
University Of Nigeria Teaching Hospital
Collaborators
Cures Within Reach
Responsible party
Ifeyinwa Nnakenyi (Consultant Chemical Pathologist and Metabolic Physician, University Of Nigeria Teaching Hospital) — Principal investigator
First posted
Dec 22, 2025
Start date
Jul 23, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Chiamaka C Onu, BSc
Contact
mowri2025@gmail.com
+2347031800855
IFEYINWA D NNAKENYI, MD
principal investigator · University Of Nigeria Teaching Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion